SAN DIEGO, Nov. 2, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months and nine months ended September 30, 2010, before the opening of trading on Tuesday, November 9.

Analyst and Investor Day

In lieu of its usual financial results conference call and webcast, Vical is hosting an Analyst and Investor Day event in New York for invited analysts and institutional investors beginning at 5:00 p.m. EST on Tuesday, November 9. A webcast of the event will be available live and archived through the Events page in the Investors section of the Vical website at www.vical.com. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at info@vical.com.

Sanjiv S. Agarwala, M.D., Chief of Oncology & Hematology and Director of the Melanoma and Immunotherapy Program at St. Luke's Cancer Center (Bethlehem, PA), will present an overview on metastatic melanoma. Mark D. Pescovitz, M.D., Professor of Surgery and Microbiology & Immunology and Vice Chair of Research in Surgery at the Indiana University School of Medicine (Indianapolis, IN), will present an overview on cytomegalovirus (CMV) in the transplant setting. Vical senior management will provide overviews on the company's technologies and programs, with a focus on the Allovectin-7^® melanoma immunotherapy program and the TransVax™ therapeutic CMV vaccine program.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

The Vical Incorporated logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5768

CONTACT:  Vical Incorporated
          Alan R. Engbring
          (858) 646-1127
          www.vical.com